2026/07/31
In 2026, WuXi AppTec DMPK marks its 20th anniversary, offering a vantage point to reflect on how the discipline, as well as its role in drug discovery, has evolved...
Read more2026/07/30
Explore how extrahepatic delivery, longer durability, and programmable RNA modalities are shaping the next era of oligonucleotide therapeutics...
Read more2026/07/28
Learn how WuXi AppTec’s integrated CRDMO platform helps small and emerging biotechs fill capability gaps and advance drug programs.
Read more2026/07/22
WuXi AppTec DMPK’s new book distills 20 years of experience into practical ADME and pharmacokinetics strategies for novel modalities, helping advance drug development and industry knowledge sharing.
Read more2026/06/02
Small molecules accounted for approximately 65% of FDA new drug approvals in 2025, continuing a resurgence that has challenged predictions of their gradual displacement by biologics and other therapeutic modalities.
Read more